---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-104940"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-09-03T12:47:46+00:00"
generated_at: "2026-09-03T12:50:09.107165+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie completes $10.9B cash acquisition of Apogee Therapeutics

## Summary
- Apogee shareholders received $135.11/share cash; total equity value ~$10.9B.
- Adds zumilokibart (IL-13 mAb for atopic dermatitis) and APG273 (asthma candidate) to immunology pipeline.
- Deal dilutive to adjusted EPS by $0.14 in 2026 and ~$0.46 in 2027; accretion expected from 2032.
- AbbVie reaffirms FY2026 adjusted EPS guidance $13.87-$14.07 and Q3 guidance $3.84-$3.88.

## SEC filing metadata
- accession: 0001104659-26-104940
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-09-03T12:47:46+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/0001104659-26-104940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-104940
- JSON: https://secwatch.observer/filing/0001104659-26-104940.json
- Plain text: https://secwatch.observer/filing/0001104659-26-104940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.